If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr. David Claxton has longstanding interests in leukemia biology and therapeutics. Leukemia molecular genetics and diagnostics are ongoing interests. Acute myeloid leukemia and related disorders are his principal foci. Leukemia therapeutics are particular interests, including drug development and clinical studies, blood and marrow transplantation, and clinical supportive care. He has a laboratory which has banked many samples of human leukemias and lymphomas. These are viably cryopreserved, used in studies and available to collaborators.

Fingerprint Dive into the research topics where David Claxton is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 11 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Targeted Sphingolipid Metabolism for Treatment of AML

Claxton, D., Kester, M., Loughran, T. P., Wang, H. G., Kester, M., Loughran, T. P., Kester, M., Wang, H. G., CABOT, M., Kester, M., Fox, T., LIAO, J., Loughran, T. P., AMIN, S., Kester, M. & Kester, M.

National Cancer Institute


Project: Research project


    Claxton, D., Kornblau, S., Arlinghaus, R. B., Reisner, Y., Austin, D., Champlin, R., Kantarjian, H., Champlin, R., Feinberg, A. & Deisseroth, A.

    National Cancer Institute


    Project: Research project


    Claxton, D., Benedict, W., Liang, J., Plunkett, W., Reed, J., Andreeff, M., Kornblau, S., Estey, E., Andreeff, M. & Champlin, R.

    National Cancer Institute


    Project: Research project

  • Research Output

    Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemia

    Pearson, J. M., Tan, S. F., Sharma, A., Annageldiyev, C., Fox, T. E., Abad, J. L., Fabrias, G., Desai, D., Amin, S., Wang, H. G., Cabot, M. C., Claxton, D. F., Kester, M., Feith, D. J. & Loughran, T. P., Jan 1 2020, In : Molecular Cancer Research. 18, 3, p. 352-363 12 p.

    Research output: Contribution to journalArticle

  • Open Access
  • The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia

    Annageldiyev, C., Gowda, K., Patel, T., Bhattacharya, P., Tan, S. F., Iyer, S., Desai, D., Dovat, S., Feith, D. J., Loughran, T. P., Amin, S., Claxton, D. & Sharma, A., Mar 1 2020, In : Haematologica. 105, 3, p. 687-696 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation

    Tan, S. F., Dunton, W., Liu, X., Fox, T. E., Morad, S. A. F., Desai, D., Doi, K., Conaway, M. R., Amin, S., Claxton, D. F., Wang, H. G., Kester, M., Cabot, M. C., Feith, D. J. & Loughran, T. P., Jan 1 2019, In : Journal of Lipid Research. 60, 6, p. 1078-1086 9 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    Animal mouse models of acute myeloid leukemia

    Patel, T. N., Madhunapantula, S. R. V., Annageldiyev, C., Claxton, D. & Sharma, A., 2019, Animal Models in Cancer Drug Discovery. Azmi, A. & Mohammad, R. M. (eds.). Academic Press, p. 419-438

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)